Nara Melikyan

Statistics

Publications

Citations

257

H-Index

Active since

2018

Affiliations

Médecins Sans Frontières(Current)

Partners In Health

Harvard University

Interactive Research and Development

Brigham and Women's Hospital

Nara Melikyan is an author at Médecins Sans Frontières specializing in pharmacotherapy, multidrug-resistant tuberculosis treatment, and tuberculosis control.

ORCID

Publications per year

2018–2023

Publications

Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study

Molly F. Franke, Palwasha Khan, Cathy Hewison et al. · American Journal of Respiratory and Critical Care Medicine · 2020 · 55 citations · Full text

Public Health, Pharmacotherapy, Clinical Pharmacology +13

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort

Catherine Hewison, Uzma Khan, Mathieu Bastard et al. · Clinical Infectious Diseases · 2022 · 53 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs

Helena Huerga, Uzma Khan, Mathieu Bastard et al. · Clinical Infectious Diseases · 2022 · 37 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

High prevalence of infection and low incidence of disease in child contacts of patients with drug-resistant tuberculosis: a prospective cohort study

Helena Huerga, Elisabeth Sánchez-Padilla, Nara Melikyan et al. · Archives of Disease in Childhood · 2018 · 21 citations · Full text

Public Health, Infectious Diseases, Pediatrics +17

Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis

Kwonjune J. Seung, Palwasha Khan, Molly F. Franke et al. · Clinical Infectious Diseases · 2019 · 20 citations

Public Health, Infectious Diseases, Pharmacotherapy +17

1–5 of 10